AP NEWS

Multiple Myeloma (Kahler Disease) Pipeline Review, H1 2018 - Therapeutic Assessment of 166 Companies & Drug Profiles - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering. Multiple Myeloma (Kahler Disease) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 82, 90, 3, 128, 27 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 8, 12, 1, 1, 24 and 5 molecules, respectively. Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Key Topics Covered:

Introduction Multiple Myeloma (Kahler Disease) - Overview Multiple Myeloma (Kahler Disease) - Therapeutics Development Multiple Myeloma (Kahler Disease) - Therapeutics Assessment Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Multiple Myeloma (Kahler Disease) - Drug Profiles Multiple Myeloma (Kahler Disease) - Dormant Projects Multiple Myeloma (Kahler Disease) - Discontinued Products Multiple Myeloma (Kahler Disease) - Product Development Milestones Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6nrmcq/multiple_myeloma?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006168/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Leukemia Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 04:16 PM/DISC: 09/25/2018 04:16 PM

http://www.businesswire.com/news/home/20180925006168/en

AP RADIO
Update hourly